[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100517368":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":25,"centralContacts":30,"locations":37,"responsibleParty":60,"collaborators":62,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":35,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":35,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":91,"overallStatus":40,"whyStopped":35,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"University of California, Davis","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Alendronate group","EXPERIMENTAL","Single-arm prospective cohort of 30 adult with SCD",[13],"Drug: Alendronate Sodium",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Alendronate Sodium","Administer oral alendronate 70 mg once a week x 24 weeks to all study participants",[9],[21,22,23,24],"alendronate tablet","oral alendronate","Fosamax","Binosto",[26],{"name":27,"affiliation":28,"role":29},"Oyebimpe O Adesina, MD, MS","UC Davis School of Medicine","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Leyla Y Teos, PhD","CONTACT","(916) 460-2749",null,"lyteos@health.ucdavis.edu",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"UC Davis Comprehensive Cancer Center","RECRUITING","Sacramento","California","95817","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-121.4944,38.58157,{"lat":50,"lon":49},[53,56,59],{"name":32,"role":33,"phone":54,"phoneExt":35,"email":55},"916-460-2749","lyteos@ucdavis.edu",{"name":27,"role":33,"phone":57,"phoneExt":35,"email":58},"(916) 703-5166","adesina@ucdavis.edu",{"name":27,"role":29,"phone":35,"phoneExt":35,"email":35},{"type":61,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR",[63,66],{"name":64,"class":65},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",{"name":67,"class":6},"Doris Duke Charitable Foundation","100517368","phase-2-alendronate-for-osteonecrosis-in-adults-with-sickle-cell-disease-100517368",false,"NCT06016634","Alendronate for Osteonecrosis in Adults With Sickle Cell Disease","A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease","Inclusion Criteria:\n\n* Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)\n* Ability to provide written informed consent\n* Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner\n* Negative urine pregnancy test for anyone of childbearing potential at study entry\n\nExclusion Criteria:\n\n* Pregnant women\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* Hospitalizations (for any cause) within 2 weeks of study entry","ALL","18 Years","80 Years",{"count":79,"type":80},30,"ESTIMATED","INTERVENTIONAL",[83],"PHASE2","A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis",[86,87,88,89,90],"Sickle Cell Disease","Sickle Cell Anemia","Osteonecrosis","Ischemic Necrosis","Avascular Necrosis",[92,93,94,95,96,97],"sickle cell disease","sickle cell anemia","osteonecrosis of the femoral head","hip osteonecrosis","ischemic necrosis of the femur","avascular necrosis of the femur","2026-07-14",{"date":100,"type":101},"2026-07-16","ACTUAL",{"date":103,"type":101},"2026-03-09",{"date":105,"type":80},"2027-12",{"name":5,"class":6},1]